Giant Cell Arteritis and Cardiac Comorbidity
- PMID: 33754114
- PMCID: PMC7971721
- DOI: 10.7759/cureus.13391
Giant Cell Arteritis and Cardiac Comorbidity
Abstract
Giant cell arteritis (GCA) is a large vessel vasculitis with a pathogenesis that involves two CD4 T-helper cell lineages, Th1 and Th17. The goal of GCA treatment is to achieve clinical remission and prevent complications, especially vision loss. Despite recent advances in treatment and diagnostic modalities for GCA, there continues to be a gap in the medical literature in addressing treatment and follow-up for patients with GCA after clinical remission is achieved. Of the most important issues to address in this patient population by rheumatologists and primary care physicians alike, is that of cardiovascular disease (CVD) risks in GCA patients associated with the vasculitis and its mainstay of treatment with high-dose glucocorticoids over a prolonged period of time. Physicians must be aware of the CVD events that have been observed in a higher proportion compared to the general population in GCA patients, including strokes, thoracic aortic aneurysms and dissections, myocardial infarctions, and peripheral vascular disease. This review will focus on the risk of CVD in GCA patients, with recommendations for management and follow-up.
Keywords: cardiac comorbidity; giant cell arteritis; large-vessel vasculitis and gca.
Copyright © 2021, Arias et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S114-29. Epub 2012 May 11. Clin Exp Rheumatol. 2012. PMID: 22640655 Review.
-
Prognosis and monitoring of giant cell arteritis and associated complications.Expert Rev Clin Immunol. 2018 May;14(5):379-388. doi: 10.1080/1744666X.2018.1467758. Epub 2018 Apr 26. Expert Rev Clin Immunol. 2018. PMID: 29676201 Review.
-
Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis.Arthritis Rheum. 2012 Jun;64(6):2001-11. doi: 10.1002/art.34327. Epub 2011 Dec 6. Arthritis Rheum. 2012. PMID: 22147555
-
Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis.Ther Adv Musculoskelet Dis. 2021 Jun 27;13:1759720X211006967. doi: 10.1177/1759720X211006967. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 34249150 Free PMC article.
-
Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis.Arthritis Res Ther. 2019 Dec 30;21(1):304. doi: 10.1186/s13075-019-2068-7. Arthritis Res Ther. 2019. PMID: 31888748 Free PMC article.
Cited by
-
Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis.Rheumatol Int. 2024 Apr;44(4):603-610. doi: 10.1007/s00296-023-05527-8. Epub 2024 Feb 1. Rheumatol Int. 2024. PMID: 38300269 Free PMC article.
-
Role of temporal artery resection in Horton's arteritis (Review).Exp Ther Med. 2021 Oct;22(4):1099. doi: 10.3892/etm.2021.10533. Epub 2021 Aug 2. Exp Ther Med. 2021. PMID: 34504553 Free PMC article. Review.
-
Diagnostic Dilemmas in Giant Cell Arteritis: Overcoming Anchoring Bias.Case Rep Rheumatol. 2025 Jul 21;2025:6632374. doi: 10.1155/crrh/6632374. eCollection 2025. Case Rep Rheumatol. 2025. PMID: 40726518 Free PMC article.
-
Cardiovascular lesions in giant cell arteritis.Reumatologia. 2022;60(6):399-407. doi: 10.5114/reum.2022.123670. Epub 2022 Dec 30. Reumatologia. 2022. PMID: 36683841 Free PMC article. Review.
-
Cardiology-Rheumatology Intersections in Aortitis and Aortic Aneurysms: Focus on Early Recognition and Management.JACC Case Rep. 2024 Dec 4;29(23):102818. doi: 10.1016/j.jaccas.2024.102818. eCollection 2024 Dec 4. JACC Case Rep. 2024. PMID: 39691318 Free PMC article.
References
-
- The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Hunder GG, Bloch DA, Michel BA, et al. Arthritis Rheum. 1990;33:1122–1128. - PubMed
-
- Polymyalgia rheumatica and giant cell arteritis: a systematic review. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. JAMA. 2016;315:2442–2458. - PubMed
-
- Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Lee MS, Smith SD, Galor A, Hoffman G. Arthritis Rheum. 2006;54:3306–3309. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous